Cirrhotic cardiomyopathy

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11502-11521

  Ruiz Del Arbol, Luis ^a   Serradilla, Regina ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Arterial blood volume; Cirrhosis; Cirrhotic cardiomyopathy; E e' ratio; Hepatorenal syndrome; Inotropic heart dysfunction; Left ventricular diastolic dysfunction; Liver failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANRENOIC ACID; CARBON MONOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOCANNABINOID; HORMONE PRECURSOR; INOTROPIC AGENT; TROPONIN;

APOPTOSIS; ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CHRONOTROPIC INCOMPETENCE; CHRONOTROPISM; CIRRHOTIC CARDIOMYOPATHY; CLINICAL FEATURE; DIASTOLIC DYSFUNCTION; DISEASE MARKER; HEART MUSCLE CONTRACTILITY; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INOTROPIC INCOMPETENCE; INOTROPISM; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; PROGNOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLE; SYSTOLIC DYSFUNCTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHIES; COMPLICATION; DISEASE COURSE; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION SYSTEM; HEMODYNAMICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMYOPATHIES; DISEASE PROGRESSION; HEART; HEART CONDUCTION SYSTEM; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; MYOCARDIUM; PROGNOSIS; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT;

EID: 84947289844     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11502     Document Type: Article

References (191)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-1033 [PMID: 13096569]
2. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-367 [PMID: 13520736]
3. Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969; 48: 860-868 [PMID: 4180971]
4. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989; 151: 530-535 [PMID: 2690463]
5. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, Gasbarrini G. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991; 12: 207-216 [PMID: 2050999]
6. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-275 [PMID: 11454805]
7. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, Masini A, De Castro S, Merli M. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95: 32 00-3205 [PMID: 11095342]
8. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-284 [PMID: 8833359]
9. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002 [PMID: 16510203]
10. Ruíz-Del-Arbol L, Achécar L, Serradilla R, Rodríguez-Gandía MA , Rivero M, Garrido E, Natcher JJ. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology 2013; 58: 1732-1741 [PMID: 23703953 DOI: 10.1002/hep.26509]
11. Arroyo V, Terra C. Ruiz-Del-Arbol L. Pathogenesis, Diagnosis and Treatment of Ascites in Cirrhosis. Rodés J, Benhamou JP, Blei AT, Reichen J, Rizzetto M, editors. Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd ed. Oxford: Blackwell Publishing Ltd, 2008: 666-710
12. Lewis FW, Adair O, Rector WG. Arterial vasodilation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 1992; 102: 1024-1029 [PMID: 1537494]
13. Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014; 11: 177-186 [PMID: 24217347 DOI: 10.1038/nrgastro.2013.210]
14. De BK, Majumdar D, Das D, Bis was PK, Mandal SK, Ray S, Bandopadhyay K, Das TK, Dasgupta S, Guru S. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J Hepatol 2003; 39: 315-319 [PMID: 12927915]
15. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-Del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients wit h marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217 [PMID: 12500206]
16. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 [PMID: 23993913]
17. Takeuchi O,Akira S. Pattern recognition receptors and inflammation Cell 2010 140 805-820 PMID: 20303872 DOI: 10.1016/j.cell.2010.01.022]
18. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004; 95: 1140-1153 [PMID: 15591236]
19. Tahara D, Nakanishi T, Akazawa S, Yamag uchi Y, Yamamoto H, Akashi M, Chikuba N, Okuno S, Maeda Y, Kusumoto Y. Lecithincholesterol acyltransferase and lipid transfer protein activities in liver disease. Metabolism 1993; 42: 19-23 [PMID: 844 6043]
20. Simon JB. Red cell lipids in liver disease: relationship to serum lipids and to lecithin-cholesterol acyltransferase. J Lab Clin Med 1971; 77: 891-900 [PMID: 5559858]
21. M a Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-Adrenergic receptor function in cirrhotic rats. Am J Physiol 1994; 267: G87-G93 [PMID: 8048535]
22. Moreau R, Kom eichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994; 106: 1016-1023 [PMID: 8143968]
23. Hendrickse MT, Triger DR. Peripheral and cardiovascular autonomic impairment in chronic liver disease: prevalence and relation to hepatic function. J Hepatol 1992; 16: 177-183 [PMID: 1336506]
24. Hendrickse MT, Thuluvath PJ, Triger DR. Natural history of autonomic neuropathy in chronic liver disease. Lancet 1992; 339: 1462-1464 [PMID: 1351136]
25. Bajaj BK, Agarwal MP, Ram BK. Autonomic neuropathy in patients with hepatic cirrhosis. Postgrad Med J 2003; 79: 408-411 [PMID: 12897221]
26. Dillon JF, Plevris JN, Nola n J, Ewing DJ, Neilson JM, Bouchier IA, Hayes PC. Autonomic function in cirrhosis assessed by cardiovascular reflex tests and 24-hour heart rate variability. Am J Gastroenterol 1994; 89: 1544-1547 [PMID: 8079 935]
27. Ates F, Topal E, Kosar F, Karincaoglu M, Yildirim B, Aksoy Y, Aladag M, Harputluoglu MM, Demirel U, Alan H, Hilmioglu F. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig Dis Sci 2006; 51: 1614-1618 [PMID: 16927142]
28. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292: H2966-H2972 [PMID: 17293491]
29. Frith J, Newton JL. Autonomic dysfunction in chronic liver disease. Liver Int 2009; 29: 483-489 [PMID: 19323779 DOI: 10.1111/j.1478-3231.2009.01985.x]
30. Salerno F, Cazzaniga M. Autonomic dysfunction: often present but usually ignored in patients with liver disease. Liver Int 2009; 29: 1451-1453 [PMID: 19811611 DOI: 10.1111/j.1478-3231.2009.02141.x]
31. Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, Melani L, Fantini F , Gentilini P. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113: 891-898 [PMID: 9287981]
32. Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998; 29: 328-341 [PMID: 9722218]
33. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28: 59-69 [PMID: 18293277 DOI: 10.1055/s-2008-1040321]
34. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304 [PMID: 19669380 DOI: 10.1007/s12072-008-9109-7]
35. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, Afeltra A, Sanyal AJ. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56: 539-549 [PMID: 20688208 DOI: 10.1016/j.jacc.2009.12.075]
36. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-190 [PMID: 20462649 DOI: 10.1016/j.jhep.2010.02.023]
37. Ma Z, Miyamoto A, Lee SS. Role of altered beta-Adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996; 110: 1191-1198 [PMID: 8613009]
38. Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-Adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409-1 411 [PMID: 2872517]
39. Kakimoto H, Imai Y, Kawata S, Inada M, Ito T, Matsuzawa Y. Altered lipid composition and differential changes in activities of membrane-bound enzymes of erythrocytes in hepatic cirrhosis. Metabolism 1995 ; 44: 825-832 [PMID: 7616839]
40. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-Adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1 997; 26: 904-912 [PMID: 9126806]
41. Ceolotto G, Papparella I, Sticca A, Bova S, Cavalli M, Cargnelli G, Semplicini A, Gatta A, Angeli P. An abnormal gene expression of the beta-Ad renergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology 2008; 48: 1913-1923 [PMID: 19003918 DOI: 10.1002/hep.22533]
42. Keller M, Pignier C, Niggli E, Egger M. Mechanisms of Na+-Ca2+ exchange inhibition by amphiphiles in cardiac myocytes: importance of transbilayer movement. J Membr Biol 2004; 198: 159-175 [PMID: 15216417]
43. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-376 [PMID: 7608490]
44. Jaue DN, Ma Z, Lee SS. Ca rdiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997; 25: 1361-1365 [PMID: 9185753]
45. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001; 121: 1209-1218 [PMID: 11677214]
46. de Mikulic LE, Auclair MC, Vernimmen C, Lebrec D, Mikulic E. Plasma from cirrhotic pat ients induces inotropic changes on cultured rat heart cells. Life Sci 1987; 41: 2177-2184 [PMID: 3669917]
47. Mallat A, Teixeira-Clerc F, Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol 2013; 59: 891-896 [PMID: 23567085 DOI: 10.1016/j.jhep.2013.03.032]
48. Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M, Domenicali M, Petrosino S, Giampalma E, Riili A, Grazi G, Golfieri R, Zoli M, Bernardi M, Di Marzo V. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 2010; 30: 816-825 [PMID: 19840245 DOI: 10.1111/j.1478-3231.2009.02137.x]
49. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011; 53: 346-355 [PMID: 21254182 DOI: 10.1002/hep.24077]
50. Baldassarre M, Giannone FA, Napoli L, Tovoli A, Ricci CS, Tufoni M, Caraceni P. The endocannabinoid system in advanced liv er cirrhosis: pathophysiological implication and future perspectives. Liver Int 2013; 33: 1298-1308 [PMID: 23890208 DOI: 10.1111/liv.12263]
51. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008; 54: 1-7 [PMID: 17631919]
52. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005; 146: 315-323 [PMID : 16025138]
53. Batkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007; 293: H1689-H1695 [PMID: 17557913]
54. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276: H2085-H2093 [PMID: 10362691]
55. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid rece ptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-423 [PMID: 1700516]
56. Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induce d cardiac dysfunction in cholestatic bile ductligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2010; 53: 298-306 [PMID: 20626112]
57. Piper RD. Myocardial dysfunction in sepsis. Clin Exp Pharmacol Physiol 1998; 25: 951-954 [PMID: 9807671]
58. van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996; 24: 747-752 [PMID: 8835751]
59. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroen terology 2000; 118: 937-944 [PMID: 10784593]
60. Mani AR,Ippolito S,Ollosson R,Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with bi liary cirrhosis Hepatology 2006 43 847-856 PMID: 16557556]
61. Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol 2001; 280: G68-G74 [PMID: 11123199]
62. Seddon M, Shah AM, Casadei B. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 2007; 75: 315-326 [PMID: 17568574]
63. Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts ST, Marsh JD, Houser SR. Ca2+ influx-induced sarcoplasmic reticulum Ca2 + overload causes mitochondrialdependent apoptosis in ventricular myocytes. Circ Res 2005; 97: 1009-1017 [PMID: 16210547]
64. Abbasi A, Joharimoqaddam A, Faramarzi N, Khosravi M, Jahanzad I, Dehpour AR. Opioid receptors blockade modulates apoptosis in a rat model of cirrhotic cardiomyopathy. Ann Med Health Sci Res 2014; 4: 404-409 [PMID: 24971217 DOI: 10.4103/2141-9248.133468]
65. Nam SW, Liu H, Wong JZ, Feng AY, Chu G, Merchant N, Lee SS. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice. Clin Sci (Lond) 2014; 127: 519-526 [PMID : 24712830 DOI: 10.1042/CS20130642]
66. Liu H, Lee SS. Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int 2008; 28: 640-648 [PMID: 18346133 DOI: 10.1111/j.1478-3231.2008.01692.x]
67. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-1137 [PMID: 9362352]
68. Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, Vilstrup H. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011; 31: 534-540 [PMID: 21382164 DOI: 10.1111/j.1478-3231.2011.02468.x]
69. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97: 259-267 [PMID: 10464050]
70. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, Bonnevie O, Godtfredsen J. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Card iol 1984; 54: 852-855 [PMID: 6486037]
71. Epstein M, Schneider N, Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 1977; 89: 1175-1187 [PMID: 864301]
72. Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 1085-1092 [PMID: 20453655 DOI: 10.1097/MEG.0b013e32833a4822]
73. Mikulic E, Muñoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1983; 34: 56-59 [PMID: 6861438]
74. Ramond MJ, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol 1986; 21: 191-196 [PMID: 3954935]
75. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-Adrenergic receptors i n cirrhotic rats. Hepatology 1990; 12: 481-485 [PMID: 2169452]
76. Inglés AC, Hernández I, García-EstañJ, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991; 260: H1912-H1917 [PMID: 1711789]
77. Caramelo C, Fernandez-Muñoz D, Santos JC, Blanchart A, Rodriguez-Puyol D, López-Novoa JM, Hernando L. Effect of volum e expansion on hemodynamics, capillary permeability and renal function in conscious, cirrhotic rats. Hepatology 1986; 6: 129-134 [PMID: 3943778]
78. Nesbitt GC, Mankad S. Strain and strain rate imaging in cardiomyopathy. Echocardiography 2009; 26: 337-344 [PMID: 19291019 DOI: 10.1111/j.1540-8175.2008.00867.x]
79. Nazar A, Guevara M, Sitges M, Terra C, Solá E, Guigou C, Arroyo V, Ginés P. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013; 58: 51-57 [PMID: 22989573 DOI: 10.1016/j.jhep.2012.08.027]
80. Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, Bettencourt P, Fraga J, Gama V. Systolic and d iastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int 2013; 33: 1158-1165 [PMID: 23617332 DOI: 10.1111/liv.12187]
81. Altekin RE,Caglar B,Karakas MS,Ozel D,Deger N,Demir I. Evaluation of subclinical left ventricular systolic dysfunction using two-dimensional speckle-tracking echocardiography in patients with non-Alcoholic c irrhosis Hellenic J Cardiol 2014 55 402-410 PMID: 25243439]
82. Glenn TK, Honar H, Liu H, ter Keurs HE, Lee SS. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol 2011; 55: 1249-1255 [PMID: 21703204 DOI: 10.1016/j.jhep.2011.02.030]
83. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141: 1901-1904 [PMID: 10803602]
84. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621-2628 [PMID: 9843472]
85. Lunseth JH, Olmstead EG, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. AMA Arch Intern Med 1958; 102: 405-413 [PMID: 13570726]
86. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24: 451-459 [PMID: 8690419]
87. Wroski J, Fiedor P, Kwolczak M, Górnicka B. Retrospective analysis of liver cirrhosis influence on heart walls thickn ess. Pathol Res Pract 2015; 211: 145-149 [PMID: 25468291 DOI: 10.1016/j]
88. Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-Angiotensin systems: mechanisms of cardiovas cular and renal effects. J Investig Med 2007; 55: 341-359 [PMID: 18062896]
89. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-278 [PMID: 18192456 DOI: 10.1136/gut.2006]
90. Henriksen JH, Schütten HJ, Bendtsen F, Warberg J. Circulating atrial natriuretic peptide (ANP) and central blood volume (CBV) in cirrhosis. Liver 1986; 6: 361-368 [PMID: 2952859]
91. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular dias tolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193 [PMID: 19270053 DOI: 10.1016/j.echo.2008.11.023]
92. Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, Gaudio C, Torromeo C. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 2013; 24: 172-176 [PMID: 22958907 DOI: 10.1016/j.ejim.2012.08.007]
93. Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, Burdick L. Humoral and cardiac effects of TIPS in cirrhotic patients with different "effective " blood volume. Hepatology 2003; 38: 1370-1377 [PMID: 14647047]
94. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxatio n and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533 [PMID: 9362412]
95. Raevens S, De Pauw M, Geerts A, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, Colle I. Prevalence and outcome of diastolic dysfunction in liver transplantation recipients. Acta Cardiol 20 14; 69: 273-280 [PMID: 25029872]
96. Dadhich S, Goswami A, Jain VK, Gahlot A, Kulamarva G, Bhargava N. Cardiac dysfunction in cirrhotic portal hypertension with or without ascites. Ann Ga stroenterol 2014; 27: 244-249 [PMID: 24974920]
97. Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci 2015; 60: 1141-1151 [PMID: 25404411]
98. Pellicori P, Torromeo C, Calicchia A, Ruffa A, Di Iorio M, Cleland JG, Merli M. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol 2013; 102: 859-864 [PMID: 23995321 DOI: 10.1007/s00392-013-0610-1]
99. Li X, Yu S, Li L, Han D, Dai S, Gao Y. Cirrhosis-related changes in left ventricular function and correlation with t he model for endstage liver disease score. Int J Clin Exp Med 2014; 7: 5751-5757 [PMID: 25664102]
100. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-433 [PMID: 15723320]
101. Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationshi p with bacterial endotoxemia. Dig Dis Sci 2013; 58: 3029-3036 [PMID: 23907333 DOI: 10.1007/s10620-013-2693-y]
102. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-Tinterval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34 [PMID: 9425913]
103. Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol 2007; 18: 77-82 [PMID: 17229304]
104. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: G537-G544 [PMID: 9277435]
105. Kempler P, Váradi A, Szalay F. Autonomic neuropathy and prolongation of QT-interval in liver disease. Lancet 1992; 340: 318 [PMID: 1353243]
106. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23: 1128-1134 [PMID: 8621144]
107. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005; 43: 637-644 [PMID: 16083986]
108. Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, Caraceni P, Domenicali M, Bernardi M. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated wit h transjugular intrahepatic porto-systemic shunt. J Hepatol 2003; 38: 461-467 [PMID: 12663238]
109. Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, P ieruzzi F, Vincenti A, Stella A, Mancia G, Stramba-Badiale M. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) 2009; 116: 851-859 [PMID: 19076059 DOI: 10.1042/CS20080325]
110. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplanta tion. Liver Int 2003; 23: 243-248 [PMID: 12895263]
111. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, Caraceni P, Domenicali M, Felline P, Zoli M , Bernardi M. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008; 48: 415-421 [PMID: 18194821 DOI: 10.1016/j.jhep.2007.11.012]
112. Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe Hepatology 2010; 52: 811-813 [PMID: 20812354 DOI: 10.1002/hep.23852]
113. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepat ol 2011; 55: 794-799 [PMID: 21354230 DOI: 10.1016/j.jhep.2011.01.034]
114. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D. Deleterious eff ects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017-1022 [PMID: 20583214 DOI: 10.1002/hep.23775]
115. Mandorfer M, Bota S, Schwabl P, Buc sics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T. Nonselective ? blockers increase risk for hepatorenal syndrome and death in patients with c irrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146: 1680-1690.e1 [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005]
116. Carey EJ, Douglas DD. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. Dig Dis Sci 2005; 50: 320-323 [PMID: 15745093]
117. Shin WJ, Kim YK, Song JG, Kim SH, Choi SS, Song JH, Hwang GS. Alterations in QT interval in patients undergoing living donor liver transplantation. Transplant Proc 2011; 43: 170-173 [PMID: 21335179 DOI: 10.1016/j.transproceed.2010.12.002]
118. Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, Lenzi B, Caraceni P, Domenicali M, Cavazza M, Bernardi M. QT interval prolongation by acute gastrointestinal bleeding in patients w ith cirrhosis. Liver Int 2012; 32: 1510-1515 [PMID: 22776742 DOI: 10.1111/j.1478-3231.2012.02847.x]
119. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022 [PMID: 14999113]
120. Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hep atol 2007; 47: 373-380 [PMID: 17459513]
121. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002; 36: 513-520 [PMID: 11943423]
122. Zavecz JH, Bueno O, Maloney RE, O'Donnell JM, Roerig SC, Battarbee HD. Cardiac excitation-contraction coupling in the portal hypertensive ra t. Am J Physiol Gastrointest Liver Physiol 2000; 279: G28-G39 [PMID: 10898744]
123. Dahl EK, Møller S, Kjaer A, Petersen CL, Bendtsen F, Krag A. Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scand J Gastroenterol 2014; 49: 362-372 [PMID: 24329122 DOI: 10.3109/00365521.2013.867359]
124. Kim MY,Baik SK,Won CS,Park HJ,Jeon HK,Hong HIm,Kim JW,Kim HS,Kwon SO,Kim JY,Yoo BS,Lee SH. Dobutamine stress echocardiography for evaluating cirrhotic cardiomyo pathy in liver cirrhosis Korean J Hepatol 2010 16 376-382 PMID: 21415581 DOI: 10.3350/kjhep.2010.16.4.376]
125. Ruiz-Del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-586 [PMID: 9247479]
126. Lunzer MR, Newman SP , Bernard AG, Manghani KK, Sherlock SP, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975; 2: 382-385 [PMID: 51190]
127. Bernardi M, Trevisani F, Sa ntini C, Zoli G, Baraldini M, Ligabue A, Gasbarrini G. Plasma norepinephrine, weak neurotransmitters, and renin activity during active tilting in liver cirrhosis: relationship with cardiovascular homeostasis and renal function. H epatology 1983; 3: 56-64 [PMID: 6401670]
128. Kelbaek H, Rabøl A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, Munck O, Lund JO. Haemodynamic response to exercise in patients w ith alcoholic liver cirrhosis. Clin Physiol 1987; 7: 35-41 [PMID: 3816110]
129. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-Alcoholic cirrhosis. J Hepatol 1995; 22: 326-332 [PMID: 7608484]
130. Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Ginés P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-447 [PMID: 15977202]
131. Tsang TS, Barnes ME, Gersh BJ, Baile y KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90: 1284-1289 [PMID: 12480035]
132. Ginés P, Jiménez W, Arroyo V, Navasa M, López C, Titó L, Serra A, Bosch J, Sanz G, Rivera F. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988; 8: 636-642 [PMID: 2967242]
133. Salerno F, Badalamenti S, Moser P, Lorenzano E, Incerti P, Dioguardi N. Atrial natriuretic factor in cirrhotic patients with tense as cites. Effect of large-volume paracentesis. Gastroenterology 1990; 98: 1063-1070 [PMID: 2138104]
134. Wong F, Logan A, Blendis L. Systemic hemodynamic, forearm vascular, renal, and humoral respon ses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis. Hepatology 1995; 21: 717-724 [PMID: 7875669]
135. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001; 101: 621-628 [PMID: 11724649]
136. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52: 1511-1517 [PMID: 1297014 7]
137. Goonewardena SN, Blair JE, Manuchehry A, Brennan JM, Keller M, Reeves R, Price A, Spencer KT, Puthumana J, Gheorghiade M. Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular fi lling pressures in patients referred for right heart catheterization. J Card Fail 2010; 16: 69-75 [PMID: 20123321 DOI: 10.1016/j.cardfail.2009.08.004]
138. Raedle-Hurst TM, Welsch C, Foresti er N, Kronenberger B, Hess G, Herrmann E, Zeuzem S, Raedle J. Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008; 20: 865-873 [PMID: 18794600 DOI: 10.1097/MEG.0b013e3282fb7cd0]
139. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, Moreau R, Langlet P, Elman A, Bernuau J, Valla D, Erlinger S, Lebrec D. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-643 [PMID: 10051461]
140. Wiese S, Mortensen C, G øtze JP, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int 2014; 34: e19-e30 [PMID: 24313898 DOI: 10.1111/liv.12428]
141. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, AndréS, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 mark s activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3128 [PMID: 15520318]
142. Kimer N, Goetze JP, Bendtsen F, Møller S. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. Eur J Clin Invest 2014; 44: 441-452 [PMID: 24476551 DOI: 10.1111/eci.12249]
143. Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007; 2: 15 [PMID: 17389039 DOI: 10.1186/1750-1172-2-15]
144. Rodriguez L, Garcia M, Ares M, Griffin BP, Nakatani S, Thomas JD. Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. Am Heart J 1996; 131: 982-987 [PMID: 8615320]
145. Gaasch WH,Battle WE,Oboler AA,Banas JS,Levine HJ. Left ventricular stress and compliance in man With special reference to normalized ventricular function curves. Circ ulation 1972 45 746-762 PMID: 4259418]
146. Ruiz-Del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, Albillos A, Jiménez W, Arroyo V. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-1218 [PMID: 14578859]
147. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 105-110 [PMID: 19837678 DOI: 10.1136/gut.2009.180570]
148. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-S131 [PMID: 16447289]
149. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 115 1-1157 [PMID: 2971015]
150. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gas troenterol 2009; 104: 2458-2466 [PMID: 19532126 DOI: 10.1038/ajg.2009.321]
151. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, Meregaglia D, Nicolini A. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahe patic portosystemic shunt. Gut 2007; 56: 869-875 [PMID: 17135305]
152. Sampaio F, Pimenta J, Bettencourt N, Fontes-Carvalho R, Silva AP, Valente J, Bettencourt P, Fraga J, Gama V. Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. Eur J Intern Med 2014; 25: 241-246 [PMID: 24485543 DOI: 10.1016/j.ejim.2014.01.011]
153. Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, Pectasides D. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 201 2; 25: 1174-1181 [PMID: 22909305 DOI: 10.1111/j.1432-2277.2012.01547.x]
154. Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Diastolic cardiac dysfu nction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int 2014; 8: 588-594 [PMID: 26202764 DOI: 10.1007/s12072-014-9544-6]
155. Polavarapu N, Tripathi D. Live r in cardiopulmonary disease. Best Pract Res Clin Gastroenterol 2013; 27: 497-512 [PMID: 24090938 DOI: 10.1016/j.bpg.2013.06.020]
156. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748 [PMID: 10205217]
157. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, De CS, Riggio O. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2 002; 97: 142-148 [PMID: 11808939]
158. Kovács A, Schepke M, Heller J, Schild HH, Flacke S. Shortterm effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: prelimin ary results. Cardiovasc Intervent Radiol 2010; 33: 290-296 [PMID: 19730936 DOI: 10.1007/s00270-009-9696-2]
159. Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Deviére J. P ulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996; 23: 982-987 [PMID: 8621179]
160. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19: 129-132 [PMID: 8276348]
161. Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, Pomier-Layrargues G. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shun t (TIPS) in cirrhotic patients. Gut 1996; 39: 600-604 [PMID: 8944572]
162. Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portalsystemic shunting. Chest 1995; 107: 1467-1469 [PMID: 7750353]
163. Ginés P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847 [PMID: 12454841]
164. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, Kowdley KV. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol 200 4; 38: 590-594 [PMID: 15232363]
165. Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic cardiomyopathy: a cardiologist's perspective. World J Gastroenterol 2014; 20: 15492-15498 [PMID: 25400434 DOI: 10.3748/wjg.v20.i4 2.15492]
166. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49: 754-760 [PMID: 4361711]
167. Cheng CP, Igarashi Y, Little WC. Mechanism of augmented rate of left ventricular filling during exercise. Circ Res 1992; 70: 9-19 [PMID: 1345778]
168. Chayanup atkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int 2014; 8: 308-315 [PMID: 25221635]
169. Páll A, Czifra A, Vitális Z, Papp M, Paragh G, Szabó Z. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. J Gastrointestin Liver Dis 2014; 23: 301-310 [PMID: 25267959 DOI: 10.15403/jgld.2014.1121.233.apac]
170. Ramirez-Gil JF, Delcayre C, Robert V, Wassef M, Trouve P, Mougenot N, Charlemagne D, Lechat P. In vivo left ventricular function and collagen expression in aldosterone/salt-induced hypertension. J Cardiovasc Pharmacol 1998; 32: 927-934 [PMID: 9869498]
171. Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, Calchera I, Boari G, Mancia G. Cardiac, neuroadrenergic, and portal hemodyna mic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005; 100: 1110-1116 [PMID: 15842586]
172. Galbois A, Rudler M, Massard J, Fulla Y, Bennani A, Bonnefont-Rousselot D, Thibault V, Reignier S, Bourrier A, Poynard T, Thabut D. Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol 2010; 52: 839-845 [PMID: 20385427 DOI: 10.1016/j.jhep.2010.01.026]
173. Trifan A, Chiriac S, Stanciu C. Update on adrenal insufficiency in patients with liver cirrhosis. World J Gastroenterol 2013; 19: 445-456 [PMID: 23382623 DOI: 10.3748/wjg.v19]
174. Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, Roca D, Jimenez W, Ginés P, Arroyo V. Relative adrenal insufficiency in decompe nsated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 2013; 58: 1757-1765 [PMID: 23728792 DOI: 10.1002/hep.26535]
175. Theocharidou E, Krag A, Bendtsen F, Møller S, Burroughs AK. Cardiac dysfunction in cirrhosis-does adrenal function play a role A hypothesis. Liver Int 2012; 32: 1327-1332 [PMID: 22292920 DOI: 10.1111/j.1478-3231.2011.02751.x]
176. Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol 2014; 20: 15499-15517 [PMID: 25400435 DOI: 10.3748/wjg.v20.i42.15499]
177. Ripoll C, Yotti R, Bermejo J, Bañares R. The heart in liver transplantation. J Hepatol 2011; 54: 810-822 [PMID: 21145840 DOI: 10.1016/j.jhep.2010.11.003]
178. Escobar B, TauráP, Martínez-Palli G, Fondevila C, Balust J, Beltrán J, Fernández J, García-Pagán JC, García-Valdecasas JC. Stroke volume response to liver graft reperfusion stress in cirrhotic patients. World J Surg 2014; 38: 927-935 [PMID: 24132825 DOI: 10.1007/s00268-013-2289-x]
179. Aggarwal S, Kang Y, Freeman JA, Fortunato FL, Pinsky MR. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc 1987; 19: 54-55 [PMID: 3303534]
180. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995; 9: 463-471 [PMID: 8645890]
181. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 10: 1441-1453 [PMID: 155 58590]
182. Eimer MJ, Wright JM, Wang EC, Kulik L, Blei A, Flamm S, Beahan M, Bonow RO, Abecassis M, Gheorghiade M. Frequency and significance of acute heart failure following liver transplanta tion. Am J Cardiol 2008; 101: 242-244 [PMID: 18178414 DOI: 10.1016/j.amjcard.2007.08.056]
183. Raval Z, Harinstein ME, Flaherty JD. Role of cardiovascular intervention as a bridge to l iver transplantation. World J Gastroenterol 2014; 20: 10651-10657 [PMID: 25152569 DOI: 10.3748/wjg.v20.i31.10651]
184. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of c ardiac complications after liver transplantation. Transplantation 2009; 87: 763-770 [PMID: 19295324 DOI: 10.1097/TP.0b013e318198d734]
185. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freema n RB, Rand WM, Benotti PN. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest 1995; 107: 218-224 [PMID: 7813282]
186. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl 2002; 8: 690-700 [PMID: 12149762]
187. Acosta F, De La Morena G, Villegas M, Sansano T, Reche M, Beltran R, Roques V, Contreras RF, Robl es R, Bueno FS, Ramirez P, Parrilla P. Evaluation of cardiac function before and after liver transplantation. Transplant Proc 1999; 31: 2369-2370 [PMID: 10500622]
188. Torregrosa M,AguadéS,Dos L,Segura R,Gónzalez A,Evangelista A,Castell J,Margarit C,Esteban R,Guardia J,Genescá J. Cardiac alterations in cirrhosis: reversibility after liver transplantation J Hepatol 2005 42 68-74 PMID: 15629509]
189. Mittal C, Qureshi W, Singla S, Ahmad U, Huang MA. Pretransplant left ventricular diastolic dysfunction is associated with post transplant acute graft rejection and graft fa ilure. Dig Dis Sci 2014; 59: 674-680 [PMID: 24323177 DOI: 10.1007/s10620-013-2955-8]
190. Darstein F, König C, Hoppe-Lotichius M, Grimm D, Knapstein J, Mittler J, Zimmermann A, Otto G, Lang H, Galle PR, Zimmermann T. Preoperative left ventricular hypertrophy is associated with reduced patient survival after liver transplantation. Clin Transplant 2014; 28: 236-242 [PMID: 24372847 DOI: 10.1111/ctr.12304]
191. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol 2015; 28: 31-40 [PMID: 25608575]